Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients - PubMed (original) (raw)
Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients
A-C Grimmelt et al. Clin Nephrol. 2009 Feb.
Abstract
Background: Iron deficiency is common in patients with chronic kidney disease and in kidney transplant recipients.
Patients and methods: We analyzed the safety and tolerability of the new intravenous iron preparation ferric carboxymaltose (FCM) in these two patient groups. Adverse events after administration of the drug were assessed by using a questionnaire. Vital signs and laboratory data were collected before and after the application of FCM. A total of 46 FCM doses were applied to 44 patients (17 with chronic kidney disease and 27 kidney transplant recipients) either as single injection of 100 or 200 mg (n = 42) or as short infusion with up to 500 mg (n = 4).
Results: Mild and transient adverse events (metallic taste, headache, dizziness) occurred in six patients. The estimated glomerular filtration rate remained unchanged by the FCM administration.
Conclusion: We conclude that safety and tolerability of FCM were excellent. Compared with other intravenous iron preparations the considerably shorter administration time of FCM allows to save time and to reduce costs.
Similar articles
- TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U, Illigens BM, Siepmann T, Arneth B, Siegert G, Siegels D, Heigl F, Hettich R, Ramlow W, Prophet H, Bornstein SR, Julius U. Schatz U, et al. Atheroscler Suppl. 2015 May;18:199-208. doi: 10.1016/j.atherosclerosissup.2015.02.030. Atheroscler Suppl. 2015. PMID: 25936327 - Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P, Banké-Bochita J. Geisser P, et al. Arzneimittelforschung. 2010;60(6a):362-72. doi: 10.1055/s-0031-1296301. Arzneimittelforschung. 2010. PMID: 20648928 Clinical Trial. - Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Bailie GR, Mason NA, Valaoras TG. Bailie GR, et al. Hemodial Int. 2010 Jan;14(1):47-54. doi: 10.1111/j.1542-4758.2009.00409.x. Epub 2009 Nov 3. Hemodial Int. 2010. PMID: 19888949 Clinical Trial. - Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA, Keating GM. Lyseng-Williamson KA, et al. Drugs. 2009;69(6):739-56. doi: 10.2165/00003495-200969060-00007. Drugs. 2009. PMID: 19405553 Review. - Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.
Toblli JE, Angerosa M. Toblli JE, et al. Drug Des Devel Ther. 2014 Dec 11;8:2475-91. doi: 10.2147/DDDT.S55499. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25525337 Free PMC article. Review.
Cited by
- Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia.
Aktaş BY, Ata EB, Çeşmeci E, Çakır İY, Coşkunpınar M, Tahillioğlu Y, Güner G, Güven DC, Arık Z, Kertmen N, Dizdar Ö, Yalçın Ş, Aksoy S. Aktaş BY, et al. Curr Oncol. 2023 Nov 2;30(11):9689-9700. doi: 10.3390/curroncol30110703. Curr Oncol. 2023. PMID: 37999123 Free PMC article. - Treatment Options for Anemia in Kidney Transplant Patients: A Review.
Bonomini M, Di Liberato L, Sirolli V. Bonomini M, et al. Kidney Med. 2023 May 27;5(8):100681. doi: 10.1016/j.xkme.2023.100681. eCollection 2023 Aug. Kidney Med. 2023. PMID: 37415623 Free PMC article. Review. - Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease.
Gutiérrez OM. Gutiérrez OM. Kidney Int Rep. 2021 Jun 5;6(9):2261-2269. doi: 10.1016/j.ekir.2021.05.020. eCollection 2021 Sep. Kidney Int Rep. 2021. PMID: 34514189 Free PMC article. Review. - Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome.
Glaspy JA, Wolf M, Strauss WE. Glaspy JA, et al. Adv Ther. 2021 Jul;38(7):3531-3549. doi: 10.1007/s12325-021-01770-2. Epub 2021 May 30. Adv Ther. 2021. PMID: 34053011 Free PMC article. Review. - Iron deficiency after kidney transplantation.
Vinke JSJ, Francke MI, Eisenga MF, Hesselink DA, de Borst MH. Vinke JSJ, et al. Nephrol Dial Transplant. 2021 Nov 9;36(11):1976-1985. doi: 10.1093/ndt/gfaa123. Nephrol Dial Transplant. 2021. PMID: 32910168 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical